// App-Quantinova.ai

Filters

Biomarkers











Conference Name











Country

























Company

Search valid company name..

Conference Year













Drug











Disease











Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























2187 Abstracts

Social connectivity and outcomes for adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL).

Andrew Fintel - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

Prospective assessment of chemotherapy-induced peripheral neuropathy (CIPN) in children with standard-risk acute lymphoblastic leukemia (SR ALL): Results of Childrens Oncology Group (COG) AALL0932.

Nina S. Kadan-Lottick - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Peripheral Nervous System

Acute lymphoblastic leukemia

Dexamethasone

Phase II study of combination of hyperCVAD with ponatinib in frontline therapy of patients (pts) with Philadelphia chromosome (Ph) positive acute lymphoblastic leukemia (ALL).

Susan Mary OBrien - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Vincristine

Central nervous system relapse in adults with acute lymphoblastic leukemia.

Muhamed Baljevic - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Acute lymphoblastic leukemia

Nelarabine

Acute lymphoblastic leukemia treated in Iran: Improving outcome during the last 25 years.

Hassan Jalaeikhoo - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Allmercap

Outcomes of patients (pts) with acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) with bone marrow necrosis (BMN) at initial diagnosis.

Aditya Shetty - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

Factors associated with nonadherence to oral 6-mercaptopurine (6MP) in children with acute lymphoblastic leukemia (ALL): A report from Childrens Oncology Group (COG) study AALL03N1.

Wendy Landier - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

6-mercaptopurine

Correlation of childhood acute lymphoblastic leukemia subclones carrying intragenic IKZF1 deletions with relapse.

Peter Hoogerbrugge - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

Outcome of childhood acute lymphoblastic leukemia: A single center experience from India.

Rajat Sharma - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

Risk of infectious toxicity associated with polymorphism in GSTP1 in children with acute lymphoblastic leukemia in a population of Amazonia.

Alayde vieira Wanderley - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

Risk factors for oral lesions and septicemia associated in children with acute lymphoblastic leukemia in chemotherapy.

Araceli Castellanos-Toledo - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Acute lymphoblastic leukemia

N/A

Chimeric Antigen Receptor (CAR) T Cell Therapy for B Cell Cancers

R. Brentjens - International Congress on Targeted Anticancer Therapies (TAT) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

IL-12

Donor Derived Systemic Lupus Erythematosus (SLE) after Allogeneic Transplantation

Dhivya Sugumar - European Group for Blood and Marrow Transplantation (EBMT) , 2015

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Acute lymphoblastic leukemia

chloroquine

Bone Health Assessment in Patients Undergoing Hematopoietic Cell Transplantation

Daniel Ernst - European Group for Blood and Marrow Transplantation (EBMT) , 2015

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Acute lymphoblastic leukemia

Ergocalciferol

Donor Cell Leukemia: A Prospective Study of Its Identification and Treatment

Guillermo J Ruiz-Delgado - European Group for Blood and Marrow Transplantation (EBMT) , 2015

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Acute lymphoblastic leukemia

N/A

Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) Following Blinatumomab-Induced Remission in Pediatric Patients with Relapsed/Refractory (r/r) B-Precursor Acute Lymphoblastic Leukemia (ALL): Preliminary Results from a Phase I/II Stud

Rupert Handgretinger - European Group for Blood and Marrow Transplantation (EBMT) , 2015

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Acute lymphoblastic leukemia

Blinatumomab

Is Lymphoid Leukemia Less Susceptible to Busulfan Than Myeloid Leukemia? Comparison of Cytotoxicities of Busulfan, Melphalan, Fludarabine, Clofarabine, Cytosine Arabinoside, and Etoposide in Human Myeloid and Lymphoid Leukemia Cell Lines

Masaru Kamishohara - European Group for Blood and Marrow Transplantation (EBMT) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Cytarabine liposomal

Targeting BCL-2 and BCR-Abl Activity in Ph+ALL

Jessica T Leonard - European Group for Blood and Marrow Transplantation (EBMT) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

dasatinib

Routine Bone Marrow and CSF Analysis Following Allogeneic Hematopoietic Cell Transplantation (AlloHCT) in Children with Leukemia: Lack of Consensus and Questionable Utility

Anya Levinson - European Group for Blood and Marrow Transplantation (EBMT) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

Clostridium Difficile Infection in Patients Undergoing Hematopoietic Cell Transplantation. Results from the Transplantation Group at the Catholic University Hospital in Santiago, Chile

Javier Pilcante - European Group for Blood and Marrow Transplantation (EBMT) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Hydroxyzine

Copyright © 2026. QuantiNova All rights reserved